Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Opugotamig Olatansine · IMGN-151

Bispecific antibody (Biparatopic) · Cytotoxic, directed at folate receptor alpha (FOLR1) · developed by AbbVie

Phase 2 Most advanced trial

ABBV Developer

1 Registered trials

What is Opugotamig Olatansine?

Opugotamig olatansine is an antibody-drug conjugate composed of a biparatopic antibody targeting two epitopes of folate receptor alpha conjugated to the maytansinoid DM21. Upon binding FRa on tumor cells and internalization, DM21 is released to bind tubulin and disrupt microtubule dynamics, inhibiting cell division and growth. It is studied in gynecologic cancers including ovarian, fallopian tube, and primary peritoneal cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: IMGN-151
Drug type: Bispecific antibody (Biparatopic)
Targets: folate receptor alpha (FOLR1), tubulin (secondary target)
Mechanism: Cytotoxic, directed at folate receptor alpha (FOLR1)
Pathways: microtubule dynamics, cell division inhibition
Therapy area: Oncology
Developer: AbbVie (ABBV)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 8R9DRT37YD

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07024784	Phase 2	Gynecologic Cancers	Recruiting	ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fallopian Tube CancerGynecologic CancersPlatinum-Sensitive Ovarian CancerPrimary Peritoneal Cancer (PSOC)

Other drugs acting on FOLR1

ABBV-901 Phase 1 Sofetabart Mipitecan Phase 3 Torvutatug Samrotecan Phase 1 ZW191 Phase 1

More from AbbVie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Upadacitinib FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Opugotamig Olatansine

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z